SCHEMBL23577421

SCHEMBL23577421

COC(=O)c1ccc2c(N(C)c3ccccc3)nc3nncn3c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 3/20 0.40
FGFR1 P11362 1/20 0.39
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
LCK P06239 1/20 0.37
ACSS2 Q9NR19 1/20 0.37
CSNK2A2 P19784 2/20 0.36
CSNK2B P67870 2/20 0.36
HTT P42858 2/20 0.36
KIF11 P52732 1/20 0.36
ALOX15 P16050 1/20 0.36
KDM4E B2RXH2 4/20 0.36
ACLY P53396 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 2/20 0.36
THRB P10828 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909863 1.00 CSNK2A1 (0.40) CSNK2A1FGFR1GABRG2GABRB3GABRA5
SCHEMBL23576749 0.92 FGFR1 (0.42) CSNK2A1FGFR1GABRG2GABRB3GABRA5
SCHEMBL29909496 0.92 FGFR1 (0.42) CSNK2A1FGFR1GABRG2GABRB3GABRA5
SCHEMBL23578062 0.89 CSNK2A1 (0.50) CSNK2A1FGFR1CSNK2A2CSNK2BKDM4E
SCHEMBL23577364 0.87 GABRG2 (0.41) GABRG2GABRB3GABRA5GABRA3KMT2A
SCHEMBL29909321 0.87 GABRG2 (0.41) GABRG2GABRB3GABRA5GABRA3KMT2A
SCHEMBL23576795 0.84 CSNK2A1 (0.38) CSNK2A1CSNK2A2CSNK2BSMN1; SMN2MAPT
SCHEMBL29909235 0.84 CSNK2A1 (0.38) CSNK2A1CSNK2A2CSNK2BSMN1; SMN2MAPT
SCHEMBL23578083 0.83 CSNK2A1 (0.37) CSNK2A1CSNK2A2CSNK2BSMN1; SMN2MAPT
SCHEMBL23578086 0.83 CSNK2A1 (0.37) CSNK2A1CSNK2A2CSNK2BSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK CSNK2A1 1221/4885FGFR1 2969/4885GABRG2 3044/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK CSNK2A1 1221/4885FGFR1 2969/4885GABRG2 3044/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK CSNK2A1 1221/4885FGFR1 2969/4885GABRG2 3044/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK CSNK2A1 1221/4885FGFR1 2969/4885GABRG2 3044/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK CSNK2A1 1221/4885FGFR1 2969/4885GABRG2 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.